Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

NCT04472546 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2024-06-07

No results posted yet for this study

Summary

The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected. It is thus possible to follow a change in the state of the skin by looking at change in the associated molecular profile.

The PRISM laboratory (INSERM U1192) in Lille has developed an innovative system laser called SpiderMass composed of 4 parts:

1. A laser used for the micro-sampling of material in vivo,
2. A transport transfer line of the ablated particles,
3. A mass spectrometer that analyzes them in real time and generates the molecular profiles of the epidermis,
4. A data analysis procedure.

The SpiderMass(TM) is of great interest for the study of the skin because it allows non-invasive vivo characterization, and therefore without biopsy or sample preparation. In addition, it will complement techniques already used in the research center such as FTIR spectroscopy. Indeed, in acne studies the FTIR allows to obtain only the Fatty Acid Triglycerid ratio while the SpiderMass permits to detail these lipid classes by each observed molecule on the surface of the skin and follow their evolution.

Conditions

Interventions

OTHER

in-vivo mesure

* for acne of the face subgroup and its associated control : face and inner side of the forearm * for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm * for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm * for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm

OTHER

Scotch

* for acne of the face subgroup and its associated control : face and inner side of the forearm * for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm * for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm * for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm

OTHER

Lipid index

* for acne of the face subgroup and its associated control : face * for seborrheic dermatitis of scalp subgroup and its associated control: scalp * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face

OTHER

Absorbant paper

* for acne of the face subgroup and its associated control : face * for seborrheic dermatitis of scalp subgroup and its associated control: scalp * for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead

OTHER

Hydratation Index

-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)

OTHER

TransEpidermal Water Loss

-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)

Sponsors & Collaborators

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Principal Investigators

  • Thérèse NOCERA, Mrs · Centre de Recherche sur La Peau

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2023-02-02
Completion
2024-02-02

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04472546 on ClinicalTrials.gov